Waking up from some big blockbuster dreams, Pfizer scraps a $250M drug deal as data sour, safety fears rise

John Carroll

Editor & Founder

A little over 2 years after Pfizer paid Ionis $250 million cash to in-license rights to vupanorsen (AKCEA-ANGPTL3-LRx) — immediately vaulting the drug onto its list …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Waking up from some big blockbuster dreams, Pfizer scraps a $250M drug deal as data sour, safety fears rise

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Eikon Therapeutics raises $351M Series D as lead drug starts Phase 3

Leo Pharma says its yearslong makeover is about to pay off

Merck says Keytruda could be up next for IRA price cuts

Ginkgo uncertain over the future of US government funding, stock drops

Where the money is: The top 100 venture investors in biotech

How AI can address ongoing challenges in the life sciences industry

Wak­ing up from some big block­buster dreams, Pfiz­er scraps a $250M drug deal as da­ta sour, safe­ty fears rise

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Waking up from some big blockbuster dreams, Pfizer scraps a $250M drug deal as data sour, safety fears rise